-+ 0.00%
-+ 0.00%
-+ 0.00%
Novartis, Eli Lilly Back Seawolf Therapeutics' $100 Million Series A Funding Round
Share
Listen to the news
06:36 AM EST, 11/16/2026 (MT Newswires) -- Seawolf Therapeutics raised $100 million to advance its proprietary DNA delivery platform, the US-based biotechnology company said Monday. Participants in the series A funding round included founding investor Versant Ventures, Novartis' (NOVN.SW) Novartis Venture Fund, Eli Lilly (LLY.F, LLY.SW) and Alexandria Venture Investments. Trident is a redosable lipid nanoparticle-based DNA delivery system that can be used for mutant gene replacement and systemic biologics expression, among others.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending